Clinical trial · Observational
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma: an Observational Retrospective Multicenter Study
NCT06588868CI-TRIAL-00098176FIL_CTCLrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is designed to describe the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cutaneous T Cell Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
| Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Mycosis Fungoides | ALIAS | 0.90 |
| Cutaneous T-Cell Lymphoma/Sezary Syndrome | Sezary Syndrome | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients enrolled
- description
- Patients affected by Cutaneous T-cell Lymphoma who have received first dose of a systemic therapy, lasted at least 3 months, between 1 January 2016 and 31 December 2021 in a real life setting.
Primary outcomes (3)
- measure
- To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.
- timeFrame
- The endpoint will be evaluated from the beginning to the end of the study (up to 18 months)
- description
- Type of systemic therapies used in real-life settings for the treatment of CTCL according to disease stage.
- measure
- To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.
- timeFrame
- The endpoint will be evaluated from the beginning to the end of the study (up to 18 months)
- description
- Frequency of systemic therapies used in real-life settings for the treatment of CTCL according to disease stage.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria1. * Age ≥18 years. * Have received first dose of a systemic therapy, lasted at least 3 months, between 1 January 2016 and 31 December 2023. * Availability of complete medical records in order to provide protocol required variables * Signed written informed consent. Exclusion Criteria: * Patients not meeting the above-mentioned inclusion criteria. * Refuse to sign a written informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.